Mr. Travis Doupe reports

WILLOW BIOSCIENCES ANNOUNCES ANNUAL GENERAL AND SPECIAL MEETING VOTING RESULTS

Willow Biosciences Inc. has released the voting results from its annual general and special meeting of shareholders, held on July 26, 2024. A total of 27,685,611 common shares, representing approximately 21.74 per cent of the company's issued and outstanding shares, were represented at the meeting.

The shareholders approved the setting of the number of directors of Willow at five directors, and nominees were elected as directors of Willow for the ensuing year with the specific voting results being set out herein.

                          Votes for          Votes withheld    

Director               Number        %      Number        %    
  
Donald Archibald   19,248,325   77.19%   5,686,936   22.81%
Al Foreman         24,905,181   99.88%      30,080    0.12% 
Raffi Asadorian    21,273,181   85.31%   3,662,080   14.69%
Dr. Jim Lalonde    24,905,317   99.88%      29,944    0.12% 
Dr. Chris Savile   24,905,182   99.88%      30,079    0.12% 

In addition, shareholders approved the appointment of KPMG LLP as the company's auditor for the ensuing year (86.77 per cent of the votes cast being in favour). The shareholders also approved the grant of unallocated share awards issuable under Willow's share award incentive plan pursuant to the requirements of the Toronto Stock Exchange. For complete voting results on all matters approved at the meeting, please see the company's report of voting results dated July 26, 2024, available on SEDAR+.

About Willow Biosciences Inc.

Willow develops bio-based processes to manufacture ingredients for the pharmaceutical, food and beverage, and consumer markets. Willow's FutureGrown and BioOxi platforms enable large-scale production with sustainability at its core. Willow's research and development team has a proven record of developing and commercializing bio-based manufacturing processes and products to benefit its business-to-business partners and their customers.